Treating brain cancer represents one of the most complex challenges in modern oncology. The closed nature of the skull, the extreme fragility of nervous tissue, and the biological aggressiveness of certain tumors impose severe limits on conventional therapies. However, the landscape is shifting thanks to advances in molecular biology and the study of the endocannabinoid system. This article reviews, with scientific rigor, recent progress in the use of cannabinoids to address pathologies like glioblastoma multiforme, distinguishing between solid clinical evidence, promising hypotheses, and unfounded narratives.
In brief
- Biological mechanisms: Cannabinoids act by inducing apoptosis (programmed cell death) and inhibiting tumor angiogenesis.
- Clinical evidence: Studies in humans with recurrent glioblastoma show safety and potential benefits, though large-scale controlled trials are still lacking.
- Scientific rigor: It is essential to differentiate between data published in peer-reviewed journals and anecdotal testimonies lacking radiological or medical verification.
- Current trials: Clinical studies are underway to evaluate the efficacy of cannabinoid sprays combined with temozolomide.
- Therapeutic caution: Cannabis is not a panacea; its use must be integrated into a multidisciplinary oncology plan under strict medical supervision.
The challenge of brain tumors: complexity and limitations
Brain tumors, while less frequent than other cancers, present unique characteristics. The brain develops within a rigid bony compartment; therefore, any increase in volume causes immediate mechanical compression on vital structures, rapidly generating edema and irreversible neuronal damage. Furthermore, the architecture of the central nervous system is extraordinarily delicate. A small tumor can compress critical pathways, causing severe neurological deficits.
Standard treatments—surgery, radiotherapy, and chemotherapy—have limited efficacy due to their non-selective nature. These therapies destroy tumor cells but also affect surrounding healthy tissue, which restricts the possible therapeutic doses. There are various types of neoplasms: astrocytomas, oligodendrogliomas, and meningiomas, in addition to metastases originating from other organs such as the lung or breast.
Diagnosis is often complex because initial symptoms (headaches, nausea) are non-specific. However, signs such as diplopia, hemiplegia, or vision loss can provide early warnings about a tumor’s specific location.
Mechanisms of action: apoptosis and angiogenesis
To develop effective therapies, it is necessary to attack the disease without harming healthy tissue. Molecular biology has allowed for the identification of two fundamental targets in cancer:
- Apoptosis: This is the genetically programmed mechanism of cell death. Healthy cells die when they detect irreparable damage; tumor cells, due to mutations, evade this process and proliferate uncontrollably.
- Tumor angiogenesis: Tumors need oxygen and nutrients to grow. To achieve this, they recruit new blood vessels through complex cell signaling processes.
This is where cannabinoids enter the picture. The endocannabinoid system, primarily through the CB2 receptor in the context of tumors, regulates these processes. Preclinical studies have demonstrated that both THC and CBD can activate selective apoptosis in cancer cells and negatively modulate angiogenesis.
From cell cultures to patients: the case of glioblastoma
Glioblastoma multiforme is a high-grade, extremely aggressive, and resistant tumor. In Europe and the U.S., the incidence is around 2 to 3 cases per 100,000 inhabitants per year. The median survival after diagnosis is usually less than one year.
Pioneering research in this field comes from the Department of Biochemistry and Molecular Biology at the Complutense University of Madrid, led by Professor Manuel Guzmán. In 2006, the first clinical study in the world to administer THC directly into the tumor via intracranial catheters was published.
The study included nine patients with recurrent glioblastoma (after failed surgery or radiotherapy). The results indicated a median survival of 24 weeks, with observable tumor reductions in the first few weeks. Although the study design did not allow for direct comparison against a placebo to measure absolute efficacy, it confirmed that the administration was safe and well-tolerated.
Subsequently, the synergistic combination of cannabinoids with temozolomide, a standard antineoplastic agent, was explored. In vitro studies suggest that this combination enhances the therapeutic effect compared to the isolated use of either agent.
Ongoing studies and the immediate future
The pharmaceutical industry has begun to validate these hypotheses with formal clinical trials. GW Pharmaceuticals, manufacturer of the sublingual cannabinoid spray (Sativex), recently initiated a study to evaluate this treatment combined with temozolomide in patients with recurrent glioblastoma.
The primary objective is to achieve six months of progression-free survival. Although the timeframe may seem brief, it represents a significant milestone given the speed at which this pathology evolves. The results of these trials, which will include placebo-controlled phases to determine real efficacy, are expected in a few months.
Risk reduction and critical reading
Given the rise of therapeutic cannabis, it is imperative to distinguish between scientific evidence and speculation. On one hand, there are voices that deny any utility to cannabis based on ideological or moral prejudices, hindering legitimate research with bureaucratic hurdles.
At the other extreme, narratives circulate that present cannabis as a miracle cure for all diseases. These claims usually lack rigor: no verifiable references are cited, “cure” cases are anecdotal, and often the radiological images presented as proof of a cure correspond to different patients or original tumors that received no treatment.
The position of Psiconáutica.org is clear: hope must be accompanied by rigor. Patients with serious illnesses deserve access to all available resources, but within an ethical and scientific framework that guarantees their safety. Cures should not be promised, nor should established oncological treatments be replaced without conclusive evidence.
Editorial conclusion
The use of cannabinoids in brain oncology is an emerging field with real potential, supported by clear biological mechanisms and promising preliminary studies. However, science advances step by step: from animal models to cell cultures, and finally toward controlled clinical trials.
The scientific community must continue working to unravel the potential of these compounds without falling into dogmatism or excessive enthusiasm. In the meantime, caution is our best ally: stay informed through official references, always consult with healthcare professionals, and maintain a critical attitude toward any extraordinary claim.
Psychonautics involves not only navigating the sea of psychoactive substances but also understanding their complex interaction with human health. In this journey toward more specific and less toxic therapies, cannabinoids could play a relevant role, but always within the framework of evidence.
